| 49.46 -2.99 (-5.7%) | 10-13 11:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 63.62 | 1-year : | 68.79 |
| Resists | First : | 54.47 | Second : | 58.9 |
| Pivot price | 50.75 |
|||
| Supports | First : | 47.31 | Second : | 39.36 |
| MAs | MA(5) : | 50.95 |
MA(20) : | 51.06 |
| MA(100) : | 38.49  |
MA(250) : | 26.2 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 48.6 |
D(3) : | 45.8 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 58.9 | Low : | 12.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PLSE ] has closed above bottom band by 27.9%. Bollinger Bands are 28.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 53.85 - 54.16 | 54.16 - 54.44 |
| Low: | 49.56 - 49.88 | 49.88 - 50.17 |
| Close: | 51.97 - 52.5 | 52.5 - 52.99 |
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Sun, 11 Oct 2026
Pulse Biosciences, Inc. (PLSE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 09 Oct 2026
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Thu, 08 Oct 2026
Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026 - Business Wire
Wed, 07 Oct 2026
Pulse Biosciences (NasdaqCM:PLSE) Stock Price - Simply Wall Street
Wed, 07 Oct 2026
Pulse Biosciences stock reaches 164 patient study target - AD HOC NEWS
Wed, 07 Oct 2026
Pulse Biosciences hits 164-patient enrollment target in NANOPULSE-AF pivotal IDE study - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 2.065e+007 (%) |
| Held by Institutions | 71 (%) |
| Shares Short | 3,120 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.262e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 823 % |
| Return on Equity (ttm) | -44.4 % |
| Qtrly Rev. Growth | 1.19e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -50 |
| EBITDA (p.s.) | 1910.82 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.99 |
| Price to Cash Flow | 55.42 |
| Dividend | 0 |
| Forward Dividend | 3.31e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|